After months of negotiation, German drugs and crop chemicals company Bayer has secured US seeds supplier Monsanto in a deal estimated to be worth US$66b.
This latest offer was the third in a series of bids to create a company with more than 25% of the world market for seeds and pesticides.
The deal, expected to be closed by end 2017, is not without its detractors who suggest that Bayer is "neglecting the company's pharmaceutical business".
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Sep 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Sep 16
